Flowserve Corporation insider Kenneth Siegel has filed a notice to sell 3,229 shares of Flowserve common stock under SEC Rule 144. The planned sale, through Merrill Lynch on the NYSE, has an aggregate market value of $288,801.76 at the time of the notice.
The shares were acquired on May 12, 2023 as employee stock in a compensatory transaction. Flowserve had 127,030,052 shares of common stock outstanding, providing context for the relative size of this proposed insider sale.
Flowserve Corporation director John L. Garrison Jr. reported an acquisition of phantom stock on 02/11/2026 under the company’s deferred compensation plan. He received 839 shares of phantom stock at $87.37 per share, which increased his directly owned phantom stock balance to 37,041 shares.
Each phantom stock share is the economic equivalent of one share of Flowserve common stock and represents deferred director compensation. These phantom shares become payable in common stock when he terminates service as a member of Flowserve’s board of directors.
Flowserve Corporation director Ruby R. Chandy reported an acquisition of phantom stock as part of board compensation. On February 11, 2026, she received 69 units of phantom stock at an indicated value of $87.37 per unit, bringing her total directly held phantom stock to 33,193 units.
Each phantom stock unit is the economic equivalent of one share of Flowserve common stock and reflects director fees deferred under the company’s deferred compensation plan. These phantom stock units will be paid out in shares of common stock when she ceases serving on the board.
Flowserve director Cheryl H. Johnson was granted 345 shares of phantom stock on 02/11/2026 as part of her director compensation. Each phantom stock share is economically equivalent to one share of Flowserve common stock and is issued under the company’s deferred compensation plan.
After this award, Johnson beneficially owns 11,233 phantom stock shares directly. These phantom shares will be paid out in Flowserve common stock when she terminates her service on the company’s board of directors, aligning her compensation with long-term shareholder value.
Flowserve Corporation has agreed to acquire Trillium Flow Technologies’ Valves Division for $490 million in cash, adding a market-leading portfolio of highly engineered, mission-critical valves used in nuclear and traditional power generation, industrial, and critical infrastructure applications.
The deal is expected to close in mid-2026, funded through a combination of cash on hand and additional debt, and remains subject to customary closing conditions and regulatory approvals. Flowserve also released a press release and investor presentation covering its fourth-quarter and full-year 2025 financial and operating results.
Flowserve Corporation’s President and CEO, Robert Scott Rowe, reported a small share purchase through a company stock plan. On February 2, 2026, he acquired 84 shares of common stock at $78.15 per share under the non-qualified Flowserve Corporation 2024 Employee Stock Purchase Plan in a prescheduled transaction.
Following this transaction, Rowe directly owned 346,714 Flowserve common shares, reflecting his ongoing equity stake as both a director and senior executive.
Flowserve Corporation reported that board member Kenneth I. Siegel has told the Board he will not stand for re-election at the company’s 2026 annual meeting of shareholders. He will continue to serve as a director until that meeting, providing continuity through the upcoming governance cycle. The company stated that Mr. Siegel’s decision was not the result of any disagreement with management or the Board, indicating this is a planned transition rather than a dispute-driven departure.
Flowserve Corporation has completed the divestiture of all its legacy asbestos liabilities by selling its wholly owned subsidiary BW/IP – New Mexico, Inc. to Ajax HoldCo LLC, an affiliate of Acorn Investment Partners and a portfolio company of Oaktree Capital Management. At closing, BWIP was capitalized with related assets and approximately $219,000,000 in cash, including a $199,000,000 contribution from Flowserve and a $20,000,000 contribution from the buyer.
After this transaction, the asbestos-related liabilities and associated insurance assets will be removed from Flowserve’s consolidated balance sheet, while the buyer assumes management of BWIP, including claims and insurance reimbursements. The boards of the selling entities received an independent solvency opinion supporting their determination that BWIP was solvent and adequately capitalized after the divestiture.
Flowserve Corp. President & CEO, who is also a director, reported exercising stock options and selling shares of the company’s common stock. On 12/02/2025, he exercised a stock option for 114,943 shares at an exercise price of $48.63 per share, increasing his holdings. That same day, he sold 114,943 shares at a weighted average price of $70.54 per share, plus additional sales of 95,223 shares at a weighted average price of $70.39 and 2,517 shares at a weighted average price of $70.92, all in multiple transactions within stated price ranges. After these transactions, he reported owning 346,630 shares of Flowserve common stock directly.
Flowserve Corporation investor plans to sell restricted shares under Rule 144. The notice covers a proposed sale of 212,683 shares of Flowserve common stock through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $14,989,472.25 based on the figures provided. The issuer reports 127,115,509 shares of common stock outstanding, which provides context for the size of the planned sale.
The securities to be sold were acquired through restricted stock vesting on several dates in February 2024 and through the exercise of an option originally granted on May 4, 2017, with the option exercise dated December 2, 2025 and paid in cash. By signing the notice, the selling holder represents that they are not aware of any material adverse nonpublic information about Flowserve’s current or prospective operations and acknowledges that intentional misstatements or omissions can constitute federal criminal violations.